AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04224545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
Study NCT00474175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: single dose (less than 1g) of 10% benzocaine gel formulation
Study NCT00719797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control, small
Description: control pasta, small portion
Study NCT00474175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: single dose (less than 1g) of 20% benzocaine gel formulation
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental B, small
Description: experimental pasta, small portion
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental pasta C, small
Description: experimental pasta C, small portion
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control, medium
Description: control pasta, medium portion
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental pasta B, medium
Description: experimental pasta B, medium portion
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental pasta C, medium
Description: experimental pasta C, medium portion
Study NCT01199770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NL
Description: no pasta, water only
Study NCT00536835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK461364
Description: GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
Study NCT01244282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI with sensory stimulation
Description: BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
Study NCT00294398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICS Prescription + Standard Asthma ED Discharge Therapy
Description: Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily
Study NCT00294398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Asthma ED Discharge Therapy
Description: Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
Study NCT00986141 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Selective Laser Trabeculoplasty for glaucoma
Study NCT00986141 — intervention group
Intervention type: PROCEDURE
Intervention: Selective Laser Trabeculoplasty
Description: Glaucoma Treatment
Study NCT00719797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01059149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: MagPro x100 (MagVenture A/S, DANEMARK)
Study NCT01059149 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: MagPro x100 (MagVenture A/S, DANEMARK)
Study NCT04126837 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis and treatment
Description: Monocentric, Prospective and Biomedical Research excluding Health Product
Study NCT02812511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
Study NCT01629849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1021958 qd
Description: tablet
Study NCT01629849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958 bid
Description: tablets
Study NCT01629849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1021958 bid
Description: tablets
Study NCT01629849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958 qd
Description: tablet
Study NCT03165396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is the most common clinical anesthetics.
Study NCT03165396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane is the most common clinical anesthetics.
Study NCT01328119 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF
Description: Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
Study NCT02673281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut shake
Description: walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
Study NCT02673281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo shake
Description: placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
Study NCT02237027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TasP using ART regimen as per Benin guidelines
Description: Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
Study NCT02237027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrEP using Truvada
Description: Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
Study NCT03751384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Möllers Omega-3 Ekstra Sterk
Study NCT03751384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrifriend Cachexia
Study NCT00708396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
Study NCT03310125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Over-encapsulated 0.5mg tablet twice daily
Study NCT03310125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule twice daily
Study NCT01161225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-assisted asthma self-management program
Description: Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
Study NCT01161225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult-led asthma self-management program
Description: Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
Study NCT00228371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neurostimulation
Description: High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
Study NCT01948778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris™ filter
Study NCT01948778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toraymyxin Filter
Study NCT01948778 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care
Study NCT03523351 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
Study NCT03523351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Therapy
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
Study NCT02132468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin tromethamine
Description: 60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
Study NCT04027309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
Study NCT04027309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midostaurin
Description: Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
Study NCT01287247 — intervention group
Intervention type: BIOLOGICAL
Intervention: Xeomin®
Description: Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
Study NCT00915187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS/C
Description: Adjuvant to influenza vaccine
Study NCT00915187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: Influenza vaccine
Study NCT04747002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP-7888
Description: Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides
Study NCT00920816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: axitinib will be given at a starting dose of 5 mg BID with continuous dosing
Study NCT00920816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib will be given at a dose of 400 mg BID continuous dosing
Study NCT01927588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus+Tacrolimus+Prednisone
Description: Certican, introduced at Day7 post transplant + TACreduced + Steroids.
Study NCT01927588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate+Tacrolimus+Prednisone
Description: Myfortic + Tacrolimus full + Steroids, as control arm.
Study NCT00448149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
Study NCT00448149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
Study NCT03479151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
Description: MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
Study NCT03459040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha 1-Antitrypsin
Description: AAT will be given either in the hospital or the outpatient clinic two times per week.
Study NCT03247400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% simvastatin-acid sodium salt ointment
Description: 1% simvastatin-acid sodium salt ointment applied onto a predefined limb
Study NCT04622956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Injectable Solution
Description: Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial
Study NCT03860480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP with Bupivacaine 0.5%
Description: Regional anesthesia procedure with Bupivacaïne 0.5%
Study NCT03860480 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESP with Saline 0.9%
Description: Regional anesthesia procedure with Normal Saline
Study NCT03247400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% simvastatin-acid sodium salt ointment
Description: 1% simvastatin-acid sodium salt ointment applied onto a predefined limb
Study NCT04520100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Hypnosis performed by the PI
Description: The patient will receive clinical hypnosis by the PI prior to examination and listen to recorded session during their MRI.
Study NCT03247400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% atorvastatin calcium salt ointment
Description: 1% atorvastatin calcium salt ointment applied onto a predefined limb
Study NCT04520100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care by technician trained in empathic communication
Description: The patient will be taken care of by an MRI technician who has been previously trained in empathic communication.
Study NCT03183440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PREBIOTICS
Description: women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
Study NCT03183440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: women will daily take placebo (maltodextrin) from inclusion to delivery
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Belimumab
Description: Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Belimumab
Description: Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab-placebo
Description: Saline will be administered as IV infusions at Week 4 and Week 6
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard therapy (Including Immunosuppressants)
Description: Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy (Excluding Immunosuppressants)
Description: Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy (Excluding Immunosuppressants)
Description: Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid Taper
Description: Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Taper
Description: Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
Study NCT03312907 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Steroid Taper
Description: Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
Study NCT01370889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Given PO
Study NCT01370889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02629458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment by Surgical resection
Study NCT02629458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Study NCT03697356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib, Rituximab, Dexamethasone
Description: step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~* Rituximab 375 mg/m2 intravenous on day 1~* Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~* Lenalidomide 15mg p.o on day 1-21~* Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months.
Study NCT03247400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% atorvastatin calcium salt ointment
Description: 1% atorvastatin calcium salt ointment applied onto a predefined limb
Study NCT02202616 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glycopyrronium /Indacaterol maleate
Description: Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
Study NCT00367458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg atorvastatin oral daily
Study NCT00367458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients will be administered placebo
Study NCT01381640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: marketed formulation
Study NCT01381640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: Experimental formulation
Study NCT02334189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Patients receive an information letter following an avoidable visit to the Emergency Department.
Study NCT00961415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3-week cycle
Study NCT00961415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3-week cycle
Study NCT00961415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75mg/m2 iv on day 1 of each 3-week cycle
Study NCT00961415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m2 iv on day 1 of each 3-week cycle